|
Feb 20 |
PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Surviv...
Enables Potential Shorter Time to Accelerated Approval... |
|
Jan 28 |
PDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS...
NCI-Led Study Shows Median PFS of 9.6 Months Results... |
|
Jan 22 |
PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101...
Patent Enhances IP Estate for Lead Asset;... |
|
Jan 09 |
PDS Biotech Announces FDA Alignment on use of Progression Free Survival (PFS) as Primary Endpoint...
PDS Biotech Submits Amended Protocol for Phase 3... |